Drugs / CLN-619
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06381141 | Sep 2024 → Sep 2026 expected | plasma cell myeloma | Cullinan Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05117476 | Oct 2021 → Mar 2026 overdue | non-small cell lung carcinoma | Cullinan Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLN-619 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05117476 ↗ |
| Modality | Monoclonal antibody | “Anti-MICA/MICB monoclonal antibody” NCT05117476 ↗ |
| Target | MICA | “Anti-MICA/MICB antibody” NCT05117476 ↗ |
| Target | MICB | “Anti-MICA/MICB antibody” NCT05117476 ↗ |